# Revagenix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/revagenix

- Industry: Pharmaceuticals
- Headquarters: San Mateo, US
- Website: www.revagenix.com/
- Latest round: Series B (Jan 5, 2024)
- Investors on record: 2

## About

Based in California, US, and founded in 2019, Revagenix, Inc. operates as a biopharmaceutical company that offers antimicrobial treatments for infection types including cUTI, HABP/VABP, and neonatal sepsis/BSI.  In January 2024, Revagenix, Inc. raised an undisclosed amount of venture funding co-led by new investors Tenmile and Novo Holdings.  

Revagenix's primary focus lies in advancing a proprietary pipeline of highly differentiated antibiotic programs. These programs offer solutions to combat drug-resistant infections. The company's commitment to research and development is reflected in its holistic approach to understanding the complexities of the anti-infective landscape, driving the creation of novel therapeutic solutions. 

The company will use the funding to expand its antibiotic programs.

## Funding rounds

- Series B, Jan 5, 2024 — Novo Holdings, Tenmile

## Investors

- Novo Holdings — Series B
- Tenmile (https://capitalatlas.ai/funds/tenmile) — Series B